Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 24;46(12):1159-1161.
doi: 10.1093/eurheartj/ehae652.

Within-person stability of lipoprotein(a) concentration

Affiliations

Within-person stability of lipoprotein(a) concentration

Jonas Ghouse et al. Eur Heart J. .
No abstract available

Keywords: Lipoprotein(a); Measurement; Stability; Variability.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Box plot displays the absolute change in nmol/L between the baseline and follow-up measurement according to baseline reference category. Within each box plot, the horizontal lines indicate the median, the top and bottom of each box indicate the interquartile range, and the whiskers indicate the maximum and minimum values within each grouping no further than 1.5 × interquartile range from the hinge. (B) The Bland–Altman plot shows the differences between the baseline and repeat measurement of lipoprotein(a). For ease of interpretation, a random sample of 1000 individuals was selected. Each dot is coloured according to individual baseline risk category (low/intermediate/high). The black dashed line represents the mean difference, and the red dashed lines represent the 95% confidence intervals. (C) Left-hand column of bar plots shows the fraction of individuals changing risk categories from baseline to follow-up measurement according to different baseline lipoprotein(a) strata. Right-hand column of bar plots shows the fraction of individuals with an absolute change of ≥25 nmol/L within each baseline and follow-up lipoprotein(a) strata

References

    1. Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res 2016;57:1953–75. 10.1194/jlr.R071233 - DOI - PMC - PubMed
    1. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022;43:3925–46. 10.1093/eurheartj/ehac361 - DOI - PMC - PubMed
    1. Patel AP, Wang (汪敏先) M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, et al. Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. Arterioscler Thromb Vasc Biol 2021;41:465–74. 10.1161/ATVBAHA.120.315291 - DOI - PMC - PubMed
    1. Trinder M, Paruchuri K, Haidermota S, Bernardo R, Zekavat SM, Gilliland T, et al. Repeat measures of lipoprotein(a) molar concentration and cardiovascular risk. J Am Coll Cardiol 2022;79:617–28. 10.1016/j.jacc.2021.11.055 - DOI - PMC - PubMed
    1. Deshotels MR, Sun C, Nambi V, Virani SS, Matsushita K, Yu B, et al. Temporal trends in lipoprotein(a) concentrations: the atherosclerosis risk in communities study. J Am Heart Assoc 2022;11:e026762. 10.1161/JAHA.122.026762 - DOI - PMC - PubMed